Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research

被引:2
作者
Wang, Shirley, V [1 ,2 ]
Pottegard, Anton [3 ]
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA
[2] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
[3] Univ Southern Denmark, Fac Hlth Sci, Dept Publ Hlth, Clin Pharmacol Pharm & Environm Med, DK-5230 Odense M, Denmark
关键词
transparency; reproducibility; real-world evidence; open science; pharmacoepidemiology; REAL-WORLD EVIDENCE; RISK;
D O I
10.1093/aje/kwae087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Real-world evidence (RWE) studies are increasingly used to inform policy and clinical decisions. However, there remain concerns about the credibility and reproducibility of RWE studies. While there is universal agreement on the critical importance of transparent and reproducible science, the building blocks of open science practice that are common across many disciplines have not yet been built into routine workflows for pharmacoepidemiology and outcomes researchers. Observational researchers should highlight the level of transparency of their studies by providing a succinct statement addressing study transparency with the publication of every paper, poster, or presentation that reports on an RWE study. In this paper, we propose a framework for an explicit transparency statement that declares the level of transparency a given RWE study has achieved across 5 key domains: (1) protocol, (2) preregistration, (3) data, (4) code-sharing, and (5) reporting checklists. The transparency statement outlined in the present paper can be used by research teams to proudly display the open science practices that were used to generate evidence designed to inform public health policy and practice. While transparency does not guarantee validity, such a statement signals confidence from the research team in the scientific choices that were made.
引用
收藏
页码:1625 / 1631
页数:7
相关论文
共 33 条
  • [1] [Anonymous], 2022, NICE real-world evidence framework
  • [2] Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
    Arana, Alejandro
    Pottegard, Anton
    Kuiper, Josephina G.
    Booth, Helen
    Reutfors, Johan
    Calingaert, Brian
    Lund, Lars Christian
    Crellin, Elizabeth
    Schmitt-Egenolf, Marcus
    Kaye, James A.
    Gembert, Karin
    Rothman, Kenneth J.
    Kieler, Helle
    Dedman, Daniel
    Houben, Eline
    Gutierrez, Lia
    Hallas, Jesper
    Perez-Gutthann, Susana
    [J]. CLINICAL EPIDEMIOLOGY, 2021, 13 : 1141 - 1153
  • [3] Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
    Berger, Marc L.
    Sox, Harold
    Willke, Richard J.
    Brixner, Diana L.
    Eichler, Hans-Georg
    Goettsch, Wim
    Madigan, David
    Makady, Amr
    Schneeweiss, Sebastian
    Tarricone, Rosanna
    Wang, Shirley V.
    Watkins, John
    Daniel Mullins, C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) : 1033 - 1039
  • [4] Center for Open Science, WHAT ARE OPEN SCI BA
  • [5] Center for Open Science, TOP Factor
  • [6] Center for Open Science, REAL WORLD EVIDENCE
  • [7] CoMSES Network, OPEN CODE BADGE
  • [8] European Medicines Agency, GUIDANCE FORMAT CONT, VEMA/623947/2012
  • [9] European Medicines Agency, 2019, ENCEPP CODE CONDUCT
  • [10] FDA, 2018, FRAMEWORK FDAS REAL